| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Mrz―15 |
High density lipoproteins and COVID-19: preparing the next pandemic |
Marie Laurine Apalama, Floran Begue, Sébastien Tanaka, Maxime Cournot, David Couret, Olivier Meilhac, Mohammad Ryadh Pokeerbux |
| 2 |
[GO] |
2024―Aug―22 |
Lipidomic and Metabolomic Changes in Community-acquired and COVID-19 Pneumonia |
S.M. Saballs, S. Parra, N. Martínez, N. Amigó, L. Cabau, S. Iftimie, et al. (+6) R. Pavón, X. Gavaldó, X. Correig, S. Paredes, J.C. Vallvé, A. Castro |
| 3 |
[GO] |
2024―Mai―23 |
Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection |
Kusha Mohammadi, Mark W. Sleeman, Anita Boyapati, Parnian Bigdelou, Gregory P. Geba, Sergio Fazio |
| 4 |
[GO] |
2022―Jul―31 |
Fatty Acid Synthase inhibitor TVB-3166 prevents S-acylation of the Spike protein of human coronaviruses. |
Katrina Mekhail, Minhyoung Lee, Michael Sugiyama, Audrey Astori, Jonathan St-Germain, Elyse Latreille, et al. (+8) Negar Khosraviani, Kuiru Wei, Zhijie Li, James Rini, Warren L. Lee, Costin Antonescu, Brian Raught, Gregory D. Fairn |
| 5 |
[GO] |
2022―Apr―15 |
The SARS-CoV2 envelope differs from host cells, exposes pro-coagulant lipids, and is disrupted in vivo by oral rinses |
Zack Saud, Victoria J. Tyrrell, Andreas Zaragkoulias, Majd B. Protty, Evelina Statkute, Anzelika Rubina, et al. (+20) Kirsten Bentley, Daniel A. White, Patricia Dos Santos Rodrigues, Robert C. Murphy, Harald Köfeler, William J. Griffiths, Jorge Alvarez-Jarreta, Richard William Brown, Robert G. Newcombe, James Heyman, Manon Pritchard, Robert WJ. Mcleod, Arvind Arya, Ceri-Ann Lynch, David Owens, P Vince Jenkins, Niklaas J. Buurma, Valerie B. O’Donnell, David W. Thomas, Richard J. Stanton |
| 6 |
[GO] |
2021―Sep―29 |
The roles of lipids in SARS-CoV-2 viral replication and the host immune response |
Katherine N. Theken, Soon Yew Tang, Shaon Sengupta, Garret A. FitzGerald |
| 7 |
[GO] |
2021―Mrz―02 |
Association of serum HDL cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection |
James R. Hilser, Yi Han, Subarna Biswas, Janet Gukasyan, Zhiheng Cai, Ruowei Zhu, et al. (+5) W.H. Wilson Tang, Arjun Deb, Aldons J. Lusis, Jaana A. Hartiala, Hooman Allayee |
| 8 |
[GO] |
2020―Mai―27 |
Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity |
Stephen L. Sturley, Tamayanthi Rajakumar, Natalie Hammond, Katsumi Higaki, Zsuzsa Márka, Szabolcs Márka, Andrew B. Munkacsi |
|
